474 related articles for article (PubMed ID: 34620200)
1. Intratumor heterogeneity: the hidden barrier to immunotherapy against MSI tumors from the perspective of IFN-γ signaling and tumor-infiltrating lymphocytes.
Wu W; Liu Y; Zeng S; Han Y; Shen H
J Hematol Oncol; 2021 Oct; 14(1):160. PubMed ID: 34620200
[TBL] [Abstract][Full Text] [Related]
2. Tumor-Infiltrating Lymphocytes in Colorectal Cancer: The Fundamental Indication and Application on Immunotherapy.
Bai Z; Zhou Y; Ye Z; Xiong J; Lan H; Wang F
Front Immunol; 2021; 12():808964. PubMed ID: 35095898
[TBL] [Abstract][Full Text] [Related]
3. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach.
Luchini C; Bibeau F; Ligtenberg MJL; Singh N; Nottegar A; Bosse T; Miller R; Riaz N; Douillard JY; Andre F; Scarpa A
Ann Oncol; 2019 Aug; 30(8):1232-1243. PubMed ID: 31056702
[TBL] [Abstract][Full Text] [Related]
4. Mismatch Repair Status of Gastric Cancer and Its Association with the Local and Systemic Immune Response.
Shin SJ; Kim SY; Choi YY; Son T; Cheong JH; Hyung WJ; Noh SH; Park CG; Kim HI
Oncologist; 2019 Sep; 24(9):e835-e844. PubMed ID: 30894409
[TBL] [Abstract][Full Text] [Related]
5. Importance of lymph node immune responses in MSI-H/dMMR colorectal cancer.
Inamori K; Togashi Y; Fukuoka S; Akagi K; Ogasawara K; Irie T; Motooka D; Kobayashi Y; Sugiyama D; Kojima M; Shiiya N; Nakamura S; Maruyama S; Suzuki Y; Ito M; Nishikawa H
JCI Insight; 2021 May; 6(9):. PubMed ID: 33755600
[TBL] [Abstract][Full Text] [Related]
6. Evaluating mismatch repair deficiency for solid tumor immunotherapy eligibility: immunohistochemistry versus microsatellite molecular testing.
Saeed OAM; Mann SA; Luchini C; Huang K; Zhang S; Sen JD; Piredda ML; Wang M; Baldrige LA; Sperling RM; Curless KL; Cheng L
Hum Pathol; 2021 Sep; 115():10-18. PubMed ID: 34052294
[TBL] [Abstract][Full Text] [Related]
7. A subset of patients with MSS/MSI-low-colorectal cancer showed increased CD8(+) TILs together with up-regulated IFN-γ.
Kikuchi T; Mimura K; Okayama H; Nakayama Y; Saito K; Yamada L; Endo E; Sakamoto W; Fujita S; Endo H; Saito M; Momma T; Saze Z; Ohki S; Kono K
Oncol Lett; 2019 Dec; 18(6):5977-5985. PubMed ID: 31788072
[TBL] [Abstract][Full Text] [Related]
8. Heterogeneity and Adjuvant Therapeutic Approaches in MSI-H/dMMR Resectable Gastric Cancer: Emerging Trends in Immunotherapy.
Wu H; Ma W; Jiang C; Li N; Xu X; Ding Y; Jiang H
Ann Surg Oncol; 2023 Dec; 30(13):8572-8587. PubMed ID: 37667098
[TBL] [Abstract][Full Text] [Related]
9. Combination of AKT1 and CDH1 mutations predicts primary resistance to immunotherapy in dMMR/MSI-H gastrointestinal cancer.
Wang Z; Zhang Q; Qi C; Bai Y; Zhao F; Chen H; Li Z; Wang X; Chen M; Gong J; Peng Z; Zhang X; Cai J; Chen S; Zhao X; Shen L; Li J
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35705314
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy efficacy on mismatch repair-deficient colorectal cancer: From bench to bedside.
Lizardo DY; Kuang C; Hao S; Yu J; Huang Y; Zhang L
Biochim Biophys Acta Rev Cancer; 2020 Dec; 1874(2):188447. PubMed ID: 33035640
[TBL] [Abstract][Full Text] [Related]
11. Microsatellite instability and mismatch repair protein expressions in lymphocyte-predominant breast cancer.
Horimoto Y; Thinzar Hlaing M; Saeki H; Kitano S; Nakai K; Sasaki R; Kurisaki-Arakawa A; Arakawa A; Otsuji N; Matsuoka S; Tokuda E; Arai M; Saito M
Cancer Sci; 2020 Jul; 111(7):2647-2654. PubMed ID: 32449246
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of Microsatellite Instability in Intraductal Papillary Mucinous Neoplasms of the Pancreas.
Lupinacci RM; Goloudina A; Buhard O; Bachet JB; Maréchal R; Demetter P; Cros J; Bardier-Dupas A; Collura A; Cervera P; Scriva A; Dumont S; Hammel P; Sauvanet A; Louvet C; Delpéro JR; Paye F; Vaillant JC; André T; Closset J; Emile JF; Van Laethem JL; Jonchère V; Abd Alsamad I; Antoine M; Rodenas A; Fléjou JF; Dusetti N; Iovanna J; Duval A; Svrcek M
Gastroenterology; 2018 Mar; 154(4):1061-1065. PubMed ID: 29158190
[TBL] [Abstract][Full Text] [Related]
13. Heterogeneity of Mismatch Repair Status and Microsatellite Instability between Primary Tumour and Metastasis and Its Implications for Immunotherapy in Colorectal Cancers.
Evrard C; Messina S; Sefrioui D; Frouin É; Auriault ML; Chautard R; Zaanan A; Jaffrelot M; De La Fouchardière C; Aparicio T; Coriat R; Godet J; Silvain C; Randrian V; Sabourin JC; Guimbaud R; Miquelestorena-Standley E; Lecomte T; Moulin V; Karayan-Tapon L; Tachon G; Tougeron D
Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35457245
[TBL] [Abstract][Full Text] [Related]
14. Can evaluation of mismatch repair defect and TILs increase the number of triple-negative breast cancer patients eligible for immunotherapy?
Özcan D; Lade-Keller J; Tramm T
Pathol Res Pract; 2021 Oct; 226():153606. PubMed ID: 34530255
[TBL] [Abstract][Full Text] [Related]
15. Single-Agent Neoadjuvant Immunotherapy With a PD-1 Antibody in Locally Advanced Mismatch Repair-Deficient or Microsatellite Instability-High Colorectal Cancer.
Pei F; Wu J; Zhao Y; He W; Yao Q; Huang M; Huang J
Clin Colorectal Cancer; 2023 Mar; 22(1):85-91. PubMed ID: 36528470
[TBL] [Abstract][Full Text] [Related]
16. Performance of Next-Generation Sequencing for the Detection of Microsatellite Instability in Colorectal Cancer With Deficient DNA Mismatch Repair.
Ratovomanana T; Cohen R; Svrcek M; Renaud F; Cervera P; Siret A; Letourneur Q; Buhard O; Bourgoin P; Guillerm E; Dorard C; Nicolle R; Ayadi M; Touat M; Bielle F; Sanson M; Le Rouzic P; Buisine MP; Piessen G; Collura A; Fléjou JF; de Reyniès A; Coulet F; Ghiringhelli F; André T; Jonchère V; Duval A
Gastroenterology; 2021 Sep; 161(3):814-826.e7. PubMed ID: 33992635
[TBL] [Abstract][Full Text] [Related]
17. Can the tumor-agnostic evaluation of MSI/MMR status be the common denominator for the immunotherapy treatment of patients with several solid tumors?
Fanale D; Corsini LR; Scalia R; Brando C; Cucinella A; Madonia G; Dimino A; Filorizzo C; Barraco N; Bono M; Fiorino A; Magrin L; Sciacchitano R; Perez A; Russo TDB; Pantuso G; Russo A; Bazan V
Crit Rev Oncol Hematol; 2022 Feb; 170():103597. PubMed ID: 35033663
[TBL] [Abstract][Full Text] [Related]
18. Intratumoral CD8+ Lymphocyte Infiltration as a Prognostic Factor and Its Relationship With Cyclooxygenase 2 Expression and Microsatellite Instability in Endometrial Cancer.
Suemori T; Susumu N; Iwata T; Banno K; Yamagami W; Hirasawa A; Sugano K; Matsumoto E; Aoki D
Int J Gynecol Cancer; 2015 Sep; 25(7):1165-72. PubMed ID: 26111272
[TBL] [Abstract][Full Text] [Related]
19. Current Strategy to Treat Immunogenic Gastrointestinal Cancers: Perspectives for a New Era.
Shimozaki K; Nakayama I; Hirota T; Yamaguchi K
Cells; 2023 Mar; 12(7):. PubMed ID: 37048122
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy in MSI/dMMR tumors in the perioperative setting: The IMHOTEP trial.
Coutzac C; Bibeau F; Ben Abdelghani M; Aparicio T; Cohen R; Coquan E; Dubreuil O; Evesque L; Ghiringhelli F; Kim S; Lesourd S; Neuzillet C; Phelip JM; Piessen G; Rochigneux P; Samalin E; Soularue E; Touchefeu Y; Tougeron D; Zaanan A; de la Fouchardière C
Dig Liver Dis; 2022 Oct; 54(10):1335-1341. PubMed ID: 35907691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]